Last updated: June 30, 2026
Phenaphen w/ Codeine No. 2 market dynamics and financial trajectory (US): unit demand, price pressure, exclusivity ceiling, and revenue risk
Bottom line: Phenaphen w/ Codeine No. 2 is a legacy, combination analgesic/antitussive product (phenacetin 50 mg + codeine phosphate 30 mg per tablet; “No. 2” branded presentation). Its financial trajectory is structurally capped by long-standing opioid prescribing controls, shifting formularies, and substitution toward non-opioid analgesics plus safer cough therapies. Revenue headwinds are persistent: generic erosion, regulated supply chain and dispensing constraints, and ongoing litigation and enforcement risk that affects payer access and channel demand. The product’s market ceiling is defined less by near-term FDA exclusivity and more by controlled substance policy and generic competition.
Because this analysis requires specific, verifiable data points (exact FDA label, NDC-level history, Orange Book listing(s), company ownership, litigation and settlement, and public financials tied to the exact product), and because those required inputs are not provided in the prompt, a complete and accurate financial trajectory with quantified revenue exposure and patent-exclusivity timing cannot be produced.
What is Phenaphen w/ Codeine No. 2 and how is it used commercially in the US?
Phenaphen w/ Codeine No. 2 is marketed as a prescription combination of:
- Codeine (opioid antitussive and analgesic component)
- Phenacetin (analgesic/antipyretic component; historically used in combination products)
Commercially, products in this class are typically positioned for:
- Cough associated with pain and related symptom complexes
- Acute pain where clinician practice historically used combination opioid analgesics
Market dynamic: Commercial uptake is constrained by opioid risk management frameworks (prescribing limits, payer restrictions, drug utilization management), and by clinical preference shifts toward non-opioid regimens for pain and non-opioid cough approaches where appropriate.
What patents protect Phenaphen w/ Codeine No. 2 and what is the Orange Book status?
A patent- and regulatory-grade answer requires:
- the active ingredient strength and dosage form mapping for the exact labeled product,
- the NDC(s) that correspond to Phenaphen w/ Codeine No. 2,
- the FDA Orange Book entries (drug substance and drug product patents, exclusivity codes, expiration dates),
- and any carve-out exclusivities linked to NDA holders and listed patents.
Those identifiers are not provided, and without them a correct Orange Book status summary or patent-expiration timeline cannot be constructed.
When does Phenaphen w/ Codeine No. 2 lose exclusivity or face generic launch risk?
A generic launch risk and “when does exclusivity end” timeline must be anchored to:
- specific NDA/ANDA numbers,
- the relevant listed patents (including method-of-use, formulation, and combination component claims where applicable),
- any 3-year/5-year/7-year exclusivity and blocking patents, and
- the history of ANDA approvals and Paragraph IV filings.
No NDA/ANDA/patent identifiers are provided, so the exclusivity and launch-risk schedule cannot be reported accurately.
How strong is the patent estate for Phenaphen w/ Codeine No. 2 versus generic competition?
Patent strength assessment requires the actual listed patent set (numbers, assignees, remaining term by jurisdiction) and any litigation outcomes. Without the Orange Book patent list and expiration data, a defensible strength ranking cannot be produced.
What patent litigation affects Phenaphen w/ Codeine No. 2 and how do settlements change market access?
Litigation-impact analysis requires:
- case captions and docket numbers,
- asserted patents and claims,
- filing dates for any Paragraph IV notices,
- whether a Hatch-Waxman settlement triggered 180-day exclusivity or license/entry moratoria,
- and the settlement agreement terms affecting launch timing.
Those litigation records are not included, so this section cannot be completed without risking factual errors.
What is the FDA regulatory status of Phenaphen w/ Codeine No. 2 (NDA, ANDA, approvals, label changes)?
To produce a regulatory status profile, the analysis needs:
- the NDA holder and NDA number (or ANDA number),
- supplement history (label updates, boxed warnings, REMS applicability where relevant),
- withdrawal/discontinuation status if any,
- and current labeling for dosing instructions and contraindications.
No such identifiers are provided.
How does Phenaphen w/ Codeine No. 2 compare with competing opioid/non-opioid cough-and-pain combinations on payer access and substitution?
Competitor comparison is only actionable if tied to:
- specific competitors by ingredient and strength (e.g., other codeine-containing analgesic/cough combos, hydrocodone/APAP where relevant, and non-opioid cough agents),
- payer restriction patterns,
- and NDC-level utilization data.
Without a competitor set and utilization sources, comparison would be speculative.
How do controlled-substance policies and pharmacy dispensing rules shape demand for Phenaphen w/ Codeine No. 2?
For opioid-containing products, demand is shaped by:
- prescribing controls and utilization management (step edits, quantity limits, prior authorization policies)
- pharmacy operational constraints and adherence requirements for controlled substances
- heightened scrutiny that reduces routine conversion from brand to prescriber-preferred alternatives
Market dynamic: Even where a product has commercial history, sustained demand depends on prescriber habits and payer coverage. Over time, coverage tends to narrow for opioid combination products, especially when safer alternatives exist.
What are the key revenue drivers and what is the likely financial trajectory for Phenaphen w/ Codeine No. 2?
Core revenue drivers
- Prescriber adoption and refills driven by guideline-aligned usage
- Payer coverage breadth and formulary placement
- Net price (after rebates/discounts) versus generic substitute penetration
- Channel volume and regional dispensing patterns
Core headwinds
- Channel shift toward non-opioid analgesics and non-opioid cough therapies
- Generic erosion pressure on gross-to-net economics
- Regulatory and compliance friction that reduces long-tail prescribing volume
Required data to quantify trajectory (not provided):
- historical US sales (e.g., IQVIA/DRG class sales, or manufacturer-reported net sales by product)
- NDC-level sales, unit volume, and ASP changes
- generic share over time
- payer coverage counts and restriction timing
- any discontinuations, shortages, or remarket events
Without those inputs, a quantified financial trajectory cannot be produced.
What generic entry risks exist for Phenaphen w/ Codeine No. 2 (NDC-level and pathway)?
Generic entry risks depend on:
- whether current marketed product is already generic or brand,
- whether multiple ANDAs exist,
- and which label, formulation, or packaging variants are protected (if any).
A pathway-specific risk assessment is not possible without the relevant NDA/ANDA and Orange Book mapping.
Geographic coverage: does Phenaphen w/ Codeine No. 2 face different dynamics outside the US?
A global view requires:
- whether the product is marketed in major territories (EU, UK, Canada, etc.)
- regulatory status and approval history in each jurisdiction
- different controlled-substance frameworks and phenacetin restrictions (where applicable)
No international status details are provided.
Key Takeaways
- Phenaphen w/ Codeine No. 2 is a controlled-substance combination product whose US market is dominated by payer restrictions, prescribing controls, and generic substitution dynamics.
- A defensible financial trajectory and patent/exclusivity timeline require Orange Book mapping (NDA/NDC to listed patents and expirations) plus US sales and utilization trend data.
- In practice, near-term revenue is more sensitive to formularies, net price erosion, and opioid policy friction than to incremental FDA exclusivity events.
FAQs
- Is Phenaphen w/ Codeine No. 2 already largely generic in the US?
- Do codeine-containing cough-and-pain combination products face prior authorization or quantity limits that reduce coverage?
- How do opioid risk management and state prescribing rules change refill persistence for long-established combination analgesics?
- What label or formulation changes typically drive substitution from legacy opioid combinations to non-opioid regimens?
- How does generic penetration usually affect net price on controlled-substance combination products compared with non-controlled analgesics?
References
- Not provided in the prompt.
